| Prev Close | 53.80 |
| Open | 53.85 |
| Day Low/High | 53.72 / 54.50 |
| 52 Wk Low/High | 36.15 / 57.44 |
| Volume | 4.30M |
| Avg Volume | 4.91M |
AstraZeneca Plc (AZN)
54.04
0.24
0.45
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.62B |
| Market Cap | 140.59B |
| EPS | 0.50 |
| P/E Ratio | 51.77 |
| Div & Yield | 1.37 (2.57%) |
AstraZeneca's Ailment Doesn't Look Treatable
AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area.
2 Speculative Biotech Stocks for 2016
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
Asian, European Stocks Surge in the Morning of Fed Interest Rate Day
And four other things you need to know now.
Why Relypsa Is a New 'Best Idea'
It is hard to see the biotech firm not becoming a takeover target.
Greek Parliament Approves Reforms Required by Creditors
And four other things you need to know now.
Chinese Stocks Close Into Bull Market Territory
And four other things you need to know now.
4 Reasons to Buy High Dividend Yield Equities in Europe
As bond yields go negative, dividend yields shine.
Searching for a Bottom in AstraZeneca; $34.50 Is the Critical Level
Our strategy for the stock is to look to buy available weakness in the next few weeks.
When Eyeing Small Biotechs, Partnerships Are Huge
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.
Overpriced and Vulnerable: 9 Stocks to Avoid
A look at the high-priced and weak among the most expensive sectors.
Dynavax: Revisiting A 'Best Idea'
This small-cap biotech firm could be in the early stages of a big move.
China Forbids Big Shareholders to Sell Stocks for 6 Months
And four other things you need to know now.
Here Are 3 Charts Showing You Why Illumina Is a Marvel
It's almost impossible to get too excited about its success.
The Amazing Thing About the Receptos Takeover Chatter
That this could be such an open secret is beyond me.
Biotech Moves Are Anything But Crazy
New companies are coming up with major drugs.
Here Are 3 Stocks With Huge Potential
Two are biotechs and one is in cyber security.
Delta Lags Markets on Forex; Boeing Soars on 737 Production
Delta Air Lines (DAL) lagged the S&P 500 Tuesday after reporting a steep decline in passenger unit revenue in May.
Europe Officials 'Annoyed' With Greece
And four other things you need to know now.
Portfolio Managers Shop for Growth
Combined Heinz-Kraft heads a long second-quarter list.
Dynavax Technologies: A New 'Best Idea'
This vaccine maker is now closer to several important milestones.
Those Sensitive Biotechs
They are prone to being whipsawed by news.
Go With What's Worked, Part 2
Let's look at the other groups that caught fire.
Five Things to Know Now: Another Banking Probe
U.K. authorities launch another probe into banks' conduct.
Profit From the Longer Life Spans, Part 1
Americans are living much longer these days -- and there are a number of ways to invest.
Five Things to Know Now: Amazon Tumbles
Shares nosedived in after-hours trading.
A Memo to the Activists
Stop picking on PepsiCo, Allergan and Apple.
This Morning's Market Setup
Where it began. "As I mentioned earlier, the divergences seen since late summer are starting to weigh on stocks: "Underperformance of the Russell Index. "Weakening in the cumulative advance/decline line of the Nasdaq. "Contraction in the number of ...
Medtronic and Covidien Deal Is Tax Strategy Guiding Health Care M&A
In the immediate aftermath of the Obamacare rollout, pharma and healthcare M&A fell. Now, however, it's back up, on deals like Monday morning's Covidien - Medtronic announcement,
A 'Who's Who' of Tax-Domicile Targets
Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.
